Amdocs Limited, through its subsidiaries, provides software and services to communications, entertainment, media, and other service providers worldwide.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 13.87, read 2026-11-01
Ethical passes the values gate
Price62.83 USD
Fair value93.12
Ethical score92.9/100
RatingSTRONG OPPORTUNITY
Our investment reviews on this name
2026-10-11Read Markup57.59+9.1% to today ✓Distribution gives way to Markup first Markup read since August
2026-10-02Read Distribution57.59+9.1% to today Markup gives way to Distribution after a 7% slide in 5 weeks
2026-08-27Read Markup62.10+1.2% to today ✓Distribution gives way to Markup
2026-07-02Read Distribution60.09+4.6% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Amdocs Limited holds its Markup at $62.83. The statistical read favours the buyers, held for 30 days.
As held on the ledger · 2026-10-30
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 30 days
Price at the screen
$62.83
Valuation
14.25 trailing · 7.47 forward price to earnings
Values screen
PASS· score 92.9
Beta
0.45
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
14.82%
Below 33%
Interest-bearing debt is just 14.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
3.86%
Below 33%
Cash held in interest-bearing accounts and securities is 3.9% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.20%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Amdocs clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 15%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-01. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when DOX's ethical verdict changes
Today DOX passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads STRONG OPPORTUNITY: it trades at roughly a 48% discount to our $93.12 fair value, moderate competitive moat, 2.70% revenue growth.
Fair value range in USD, drawn from the 2026-10-30 screen. The gold marker is the market price at the same screen. A 48.2% margin of safety to the base estimate.
Where our models see it going: fair-value estimate $93.12, with a range of $93.12 to $125.66, dated to the 2026-10-30 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Software that keeps every phone bill accurate
Picture the back end systems that make sure your mobile bill lands correctly whether you roam in London or Lagos. Amdocs builds and runs that software for telecom and media groups worldwide. It stands out on a 6.5 times forward earnings multiple, a moderate moat, steady 16 percent return on equity and a clean ethical pass, all while our fair value shows a 77 percent margin of safety.
Revenue edges ahead at 4 percent a year with 12 percent profit margins. The business designs modular cloud tools that communications providers rely on to bill, support and manage customers. Four analysts carry a median target of 74 dollars, well above the current 52 dollar price.
Growth that slow leaves little room for error if spending at big carriers stays flat or if key clients consolidate further. Currency moves in emerging markets add another layer of volatility. Analysis, not advice.
DOX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-02Markup$62.83+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 37%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (4 analysts) rates it none, with a mean price target of $79. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$62.83+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 37%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (4 analysts) rates it none, with a mean price target of $79. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$62.83+1.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 37%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (4 analysts) rates it none, with a mean price target of $79. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$62.22+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 37%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (4 analysts) rates it none, with a mean price target of $79. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$62.21+3.7%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.7% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 37%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (4 analysts) rates it none, with a mean price target of $79. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup$59.99+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 37%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (4 analysts) rates it none, with a mean price target of $79. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markup$59.99+0.0%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 37%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (4 analysts) rates it none, with a mean price target of $79. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup$59.99-1.1%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.1% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 37%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (4 analysts) rates it none, with a mean price target of $79.
2026-10-18Markup$60.68+5.4%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.4% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 37%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (4 analysts) rates it none, with a mean price target of $79.
2026-10-11Markup · changed$57.59+0.0%Entry 7
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 37%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (4 analysts) rates it none, with a mean price target of $79.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
